Pelizaeus-Merzbacher Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Pelizaeus-Merzbacher disease markets are expected to exhibit a CAGR of 7.37% during 2024-2034.
The Pelizaeus-Merzbacher disease market has been comprehensively analyzed in IMARC's new report titled "Pelizaeus-Merzbacher Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pelizaeus-Merzbacher disease (PMD) refers to a rare and progressive neurological disorder that primarily affects the central nervous system's myelin sheath, the protective covering of nerve fibers. This condition is characterized by a wide spectrum of symptoms, which typically emerge within the first few months of life. Infants suffering from PMD often exhibit delayed motor development, muscle weakness, and difficulty controlling movement. As the disease advances, additional symptoms, such as spasticity, tremors, and impaired coordination, become more pronounced. The diagnosis of the illness involves a combination of clinical assessment, neuroimaging techniques, and genetic testing. Magnetic resonance imaging scans of the head can reveal characteristic white matter abnormalities, a hallmark of the disease. Genetic testing, often through DNA analysis, is also utilized to identify mutations in the PLP1 gene, which encodes a crucial protein in myelin formation. These diagnostic methods enable accurate differentiation from various other similar conditions, aiding in the timely and precise diagnosis of PMD.
The increasing cases of genetic mutations that can lead to abnormal myelin formation, predominantly affecting the central nervous system and resulting in severe neurological impairments, are primarily driving the Pelizaeus-Merzbacher disease market. In addition to this, the inflating utilization of effective therapeutic interventions, such as symptomatic treatments to manage muscle spasticity, antiepileptic drugs to control seizures, and physical therapy to enhance motor function, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive care and rehabilitative measures, owing to their role in promoting independent living for patients, is further augmenting the market growth. Apart from this, the rising usage of stem cell therapies, which hold the potential to replace damaged cells and restore proper myelin production in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of assistive devices like wheelchairs, walkers, and communication devices, since they offer a substantial improvement in the quality of life by facilitating mobility and interaction, is also augmenting the market growth. Furthermore, the escalating application of gene therapy approaches designed to correct or replace the faulty PLP1 gene is expected to drive the Pelizaeus-Merzbacher disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Pelizaeus-Merzbacher disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Pelizaeus-Merzbacher disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Pelizaeus-Merzbacher disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Pelizaeus-Merzbacher disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Pelizaeus-Merzbacher disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Pelizaeus-Merzbacher disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Pelizaeus-Merzbacher disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Pelizaeus-Merzbacher disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Pelizaeus-Merzbacher disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Pelizaeus-Merzbacher disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Pelizaeus-Merzbacher disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Pelizaeus-Merzbacher disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Pelizaeus-Merzbacher disease across the seven major markets?
What is the size of the Pelizaeus-Merzbacher disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Pelizaeus-Merzbacher disease?
What will be the growth rate of patients across the seven major markets?
Pelizaeus-Merzbacher Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Pelizaeus-Merzbacher disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Pelizaeus-Merzbacher disease market?
What are the key regulatory events related to the Pelizaeus-Merzbacher disease market?
What is the structure of clinical trial landscape by status related to the Pelizaeus-Merzbacher disease market?
What is the structure of clinical trial landscape by phase related to the Pelizaeus-Merzbacher disease market?
What is the structure of clinical trial landscape by route of administration related to the Pelizaeus-Merzbacher disease market?
The Pelizaeus-Merzbacher disease market has been comprehensively analyzed in IMARC's new report titled "Pelizaeus-Merzbacher Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Pelizaeus-Merzbacher disease (PMD) refers to a rare and progressive neurological disorder that primarily affects the central nervous system's myelin sheath, the protective covering of nerve fibers. This condition is characterized by a wide spectrum of symptoms, which typically emerge within the first few months of life. Infants suffering from PMD often exhibit delayed motor development, muscle weakness, and difficulty controlling movement. As the disease advances, additional symptoms, such as spasticity, tremors, and impaired coordination, become more pronounced. The diagnosis of the illness involves a combination of clinical assessment, neuroimaging techniques, and genetic testing. Magnetic resonance imaging scans of the head can reveal characteristic white matter abnormalities, a hallmark of the disease. Genetic testing, often through DNA analysis, is also utilized to identify mutations in the PLP1 gene, which encodes a crucial protein in myelin formation. These diagnostic methods enable accurate differentiation from various other similar conditions, aiding in the timely and precise diagnosis of PMD.
The increasing cases of genetic mutations that can lead to abnormal myelin formation, predominantly affecting the central nervous system and resulting in severe neurological impairments, are primarily driving the Pelizaeus-Merzbacher disease market. In addition to this, the inflating utilization of effective therapeutic interventions, such as symptomatic treatments to manage muscle spasticity, antiepileptic drugs to control seizures, and physical therapy to enhance motor function, is also creating a positive outlook for the market. Moreover, the widespread adoption of supportive care and rehabilitative measures, owing to their role in promoting independent living for patients, is further augmenting the market growth. Apart from this, the rising usage of stem cell therapies, which hold the potential to replace damaged cells and restore proper myelin production in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of assistive devices like wheelchairs, walkers, and communication devices, since they offer a substantial improvement in the quality of life by facilitating mobility and interaction, is also augmenting the market growth. Furthermore, the escalating application of gene therapy approaches designed to correct or replace the faulty PLP1 gene is expected to drive the Pelizaeus-Merzbacher disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Pelizaeus-Merzbacher disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Pelizaeus-Merzbacher disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Pelizaeus-Merzbacher disease market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Pelizaeus-Merzbacher disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Pelizaeus-Merzbacher disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Pelizaeus-Merzbacher disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the Pelizaeus-Merzbacher disease market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Pelizaeus-Merzbacher disease market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Pelizaeus-Merzbacher disease market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Pelizaeus-Merzbacher disease across the seven major markets?
What is the number of prevalent cases (2018-2034) of Pelizaeus-Merzbacher disease by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Pelizaeus-Merzbacher disease by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Pelizaeus-Merzbacher disease across the seven major markets?
What is the size of the Pelizaeus-Merzbacher disease patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Pelizaeus-Merzbacher disease?
What will be the growth rate of patients across the seven major markets?
Pelizaeus-Merzbacher Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Pelizaeus-Merzbacher disease drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Pelizaeus-Merzbacher disease market?
What are the key regulatory events related to the Pelizaeus-Merzbacher disease market?
What is the structure of clinical trial landscape by status related to the Pelizaeus-Merzbacher disease market?
What is the structure of clinical trial landscape by phase related to the Pelizaeus-Merzbacher disease market?
What is the structure of clinical trial landscape by route of administration related to the Pelizaeus-Merzbacher disease market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PELIZAEUS-MERZBACHER DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PELIZAEUS-MERZBACHER DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PELIZAEUS-MERZBACHER DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PELIZAEUS-MERZBACHER DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PELIZAEUS-MERZBACHER DISEASE - UNMET NEEDS
10 PELIZAEUS-MERZBACHER DISEASE - KEY ENDPOINTS OF TREATMENT
11 PELIZAEUS-MERZBACHER DISEASE - MARKETED PRODUCTS
11.1 List of Pelizaeus-Merzbacher Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PELIZAEUS-MERZBACHER DISEASE - PIPELINE DRUGS
12.1 List of Pelizaeus-Merzbacher Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PELIZAEUS-MERZBACHER DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PELIZAEUS-MERZBACHER DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PELIZAEUS-MERZBACHER DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pelizaeus-Merzbacher Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pelizaeus-Merzbacher Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pelizaeus-Merzbacher Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pelizaeus-Merzbacher Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pelizaeus-Merzbacher Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pelizaeus-Merzbacher Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pelizaeus-Merzbacher Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pelizaeus-Merzbacher Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
16 PELIZAEUS-MERZBACHER DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PELIZAEUS-MERZBACHER DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PELIZAEUS-MERZBACHER DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 PELIZAEUS-MERZBACHER DISEASE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 PELIZAEUS-MERZBACHER DISEASE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 PELIZAEUS-MERZBACHER DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 PELIZAEUS-MERZBACHER DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 PELIZAEUS-MERZBACHER DISEASE - UNMET NEEDS
10 PELIZAEUS-MERZBACHER DISEASE - KEY ENDPOINTS OF TREATMENT
11 PELIZAEUS-MERZBACHER DISEASE - MARKETED PRODUCTS
11.1 List of Pelizaeus-Merzbacher Disease Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 PELIZAEUS-MERZBACHER DISEASE - PIPELINE DRUGS
12.1 List of Pelizaeus-Merzbacher Disease Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. PELIZAEUS-MERZBACHER DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. PELIZAEUS-MERZBACHER DISEASE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 PELIZAEUS-MERZBACHER DISEASE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Pelizaeus-Merzbacher Disease - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Pelizaeus-Merzbacher Disease - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Pelizaeus-Merzbacher Disease - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Pelizaeus-Merzbacher Disease - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Pelizaeus-Merzbacher Disease - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Pelizaeus-Merzbacher Disease - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Pelizaeus-Merzbacher Disease - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Pelizaeus-Merzbacher Disease - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Pelizaeus-Merzbacher Disease - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Pelizaeus-Merzbacher Disease - Access and Reimbursement Overview
16 PELIZAEUS-MERZBACHER DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 PELIZAEUS-MERZBACHER DISEASE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 PELIZAEUS-MERZBACHER DISEASE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
